Molecular Targeted Therapy
"Molecular Targeted Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease.
| Descriptor ID |
D058990
|
| MeSH Number(s) |
E02.319.574
|
| Concept/Terms |
Molecular Targeted Therapy- Molecular Targeted Therapy
- Molecular Targeted Therapies
- Targeted Therapies, Molecular
- Targeted Therapy, Molecular
- Therapies, Molecular Targeted
- Therapy, Molecular Targeted
- Targeted Molecular Therapy
- Molecular Therapies, Targeted
- Molecular Therapy, Targeted
- Targeted Molecular Therapies
- Therapies, Targeted Molecular
- Therapy, Targeted Molecular
|
Below are MeSH descriptors whose meaning is more general than "Molecular Targeted Therapy".
Below are MeSH descriptors whose meaning is more specific than "Molecular Targeted Therapy".
This graph shows the total number of publications written about "Molecular Targeted Therapy" by people in this website by year, and whether "Molecular Targeted Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 6 | 6 |
| 2011 | 5 | 15 | 20 |
| 2012 | 8 | 11 | 19 |
| 2013 | 2 | 14 | 16 |
| 2014 | 7 | 11 | 18 |
| 2015 | 6 | 12 | 18 |
| 2016 | 9 | 20 | 29 |
| 2017 | 11 | 9 | 20 |
| 2018 | 8 | 8 | 16 |
| 2019 | 6 | 16 | 22 |
| 2020 | 8 | 18 | 26 |
| 2021 | 6 | 10 | 16 |
| 2022 | 1 | 3 | 4 |
| 2023 | 1 | 1 | 2 |
| 2024 | 2 | 4 | 6 |
| 2025 | 1 | 4 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Molecular Targeted Therapy" by people in Profiles.
-
Current and emerging treatment perspectives for adults with Waldenstr?m macroglobulinemia. Expert Rev Anticancer Ther. 2025 May; 25(5):485-497.
-
Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era. Blood Adv. 2025 Mar 25; 9(6):1356-1365.
-
Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma. J Immunother Cancer. 2025 Feb 12; 13(2).
-
Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments. Hematol Oncol Clin North Am. 2025 Feb; 39(1):207-220.
-
HER2-Positive Breast Cancer Treatment and Resistance. Adv Exp Med Biol. 2025; 1464:495-525.
-
Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations. Haematologica. 2025 Jan 01; 110(1):22-36.
-
Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2025 Jan-Feb; 75(1):46-67.
-
Targeted radionuclide therapy for gliomas: Emerging clinical trial landscape. Neuro Oncol. 2024 Dec 09; 26(Supplement_9):S208-S214.
-
Mutation- and MRD-informed treatments for transplant-ineligible patients. Hematology Am Soc Hematol Educ Program. 2024 12 06; 2024(1):168-177.
-
Determining Line of Therapy from Real-World Data in Non-Small Cell Lung Cancer. Pharmacoepidemiol Drug Saf. 2024 12; 33(12):e70049.